Introduction to Biosimilars
Biosimilars are a rapidly growing treatment option for physicians managing advanced diseases, with over 20 unique biosimilars expected to enter the U.S. healthcare market in the next decade. These products offer safe and effective treatment alternatives. While similar to their reference biologics, biosimilars undergo a comprehensive FDA review process, including analytical, animal, and clinical studies. This stringent approval process ensures that they are safe and efficacious, providing therapeutic options for serious diseases.
Benefits of Biosimilars Adoption
Incorporating biosimilars into patient treatment decisions can improve access to life-saving medications and reduce overall healthcare costs through increased competition. McKesson offers a range of services to support biosimilar adoption in practices, enabling healthcare providers, payers, and patients to benefit from the availability of these cost-effective therapies.
Available Biosimilars through McKesson
McKesson provides a variety of biosimilars, such as Tofidence (tocilizumab-bavi), Tyenne (tocilizumab-aazg), Alymsys (bevacizumab-maly), and many more. These biosimilars offer therapeutic alternatives to their reference drugs, with corresponding patient support services and full prescribing information available.
Reasons to Consider Biosimilars
There are four compelling reasons to consider adopting biosimilars: expanding treatment options for complex diseases, achieving substantial cost savings on expensive therapies, accessing FDA-approved safe and effective treatments, and receiving support from leading medical advisory organizations. By exploring biosimilars, healthcare providers can enhance patient care while optimizing practice efficiency.
Biosimilar Resources and Support
McKesson offers resources such as the Biosimilar Master Class, which helps providers understand biosimilars from the FDA perspective. Additionally, the company provides guides on navigating the biosimilar landscape, identifying economic opportunities, and supporting physicians in evaluating biosimilars for their patients. McKesson's experts address clinical, operational, and economic challenges associated with biosimilar adoption, ensuring a seamless transition to these innovative treatment options.